520A.T
J-Pharma Co.,Ltd.
グロース · 医薬品 · 医薬品 · JP
JPY 349.00
−10.74%Income statement
| Metric | 2026 |
|---|---|
| Revenue | |
| Total Revenue | — |
| Cost of Revenue | — |
| Gross Profit | — |
| Operating Expenses | |
| R&D Expense | — |
| SG&A Expense | — |
| General & Admin Expense | — |
| Selling & Marketing Expense | — |
| Other Expenses | — |
| Total Operating Expenses | — |
| Cost and Expenses | — |
| Operating Income (EBIT) | (3.7B) |
| Non-Operating | |
| Interest Income | 2.9M |
| Interest Expense | — |
| Net Interest Income | — |
| Other Non-Op Income/Expense | 1.1B |
| Non-Operating Income (excl Interest) | 1.1B |
| EBT (Pre-Tax Income) | (2.5B) |
| Income Tax Expense | 1.1M |
| Bottom Line | |
| Net Income | (2.5B) |
| Earnings from Cont. Ops | — |
| Earnings from Discont. Ops | — |
| Bottom Line Net Income | (2.5B) |
| Per Share | |
| Basic EPS | (¥195) |
| Diluted EPS | (¥195) |
| Revenue Per Share | — |
| Shares | |
| Basic Shares Outstanding | 12.6M |
| Diluted Shares Outstanding | — |
| Profitability Metrics | |
| EBITDA | (3.7B) |
| D&A | 1.2M |
| EBIT | (3.7B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026